Evidence map›Paper›PMID 42206095›Full record

ArticleJTO clinical and research reports2026

Organized Lung Cancer Screening of Subjects Occupationally Exposed to Lung Carcinogens: The LUng Cancer Screening Occupational exposure Study Entry Findings.

Fleur Delva, Sébastien Gendarme, Luca Boudet, Maeva Zysman, Claire Fuhrman, Pierre-Yves Brillet, Patrick Brochard, Christophe Paris, Olivier Bylicki, Véronique Le Denmat and 13 more

Abstract read
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Fleur DelvaEpicene, INSERM U1219, University Bordeaux, France.
Sébastien GendarmeService de Pneumologie et Oncologie Thoracique, APHP Hôpital Tenon et Université Paris-Est-Créteil, Inserm, IMRB (CEpiA Team), Créteil, France.
Luca BoudetInstitut Santé-Travail Paris-Est, Centre Hospitalier Intercommunal de Créteil, France.
Maeva ZysmanInstitut Lyric, Université de Bordeaux-Inserm U1045, Pessac, France.
Claire FuhrmanService de Pneumologie, CHI de Créteil, UPEC, Créteil, France.
Pierre-Yves BrilletService de radiologie, Hôpital Avicenne, INSERM 1272, Université Paris 13, Bobigny, France.
Patrick BrochardEpicene, INSERM U1219, University Bordeaux, France.
Christophe ParisService de Maladies Professionnelles, CHU de Rennes, Rennes, France.
Olivier BylickiService de Pneumologie, HIA Sainte-Anne, Toulon, Ecole du Val de Grace, Paris, France.
Véronique Le DenmatCentre de Pathologies Professionnelles et Environnementales, CHU de Brest, Brest, France.
Brice LoddéCentre de Pathologies Professionnelles et Environnementales, CHU de Brest, Brest, France.
Milia BelacelInstitut Santé-Travail Paris-Est, Centre Hospitalier Intercommunal de Créteil, France.
Nadia AbdessemedService de pathologies professionnelles et de l'environnement, Centre Hospitalier Intercommunal de Créteil, France.
Murielle DespagneService Santé Travail Environnement, CHU de Bordeaux, Bordeaux, France.
Kellian JaunasService Santé Travail Environnement, CHU de Bordeaux, Bordeaux, France.
Aude LacourtEpicene, INSERM U1219, University Bordeaux, France.
Bénédicte ClinINSERM U1086 "ANTICIPE,", Caen, France.
Jean-François GehannoInstitut de maladies professionnelles, CHU de Rouen, France.
François LaurentInstitut Lyric, Université de Bordeaux-Inserm U1045, Pessac, France.
Gael DournesInstitut Lyric, Université de Bordeaux-Inserm U1045, Pessac, France.
Simone Mathoulin-PélissierEpicene, INSERM U1219, University Bordeaux, France.
Christos ChouaïdService de Pneumologie, CHI de Créteil, UPEC, Créteil, France.
Jean-Claude PaironInstitut Santé-Travail Paris-Est, Centre Hospitalier Intercommunal de Créteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The LUng Cancer Screening Occupational exposure (LUCSO) program was designed as a feasibility study of organized screening for lung cancer in subjects with occupational exposure to lung carcinogens in France. Herein, we report the program's entry-level (baseline) findings. Methods: The inclusion criteria were subjects aged 55 to 74 years, with sufficient exposure to International Agency for Research on Cancer group 1 occupational carcinogens and smoker or ex-smoker for less than 15 years. The first phase of the study addressed subjects aged 65 to 74 years in two French regional counties to test feasibility. Lung cancer screening was based on a low-dose computed tomography (CT) scan at baseline and spirometry, followed by an annual CT scan for 2 years and telephone follow-up at 3 years. Results: Letters were sent to 247,152 subjects from the Regional Cancer Screening Coordination Center inviting them to participate, allowing eligibility screening by letter. Among the 21,502 respondents (8.7%), 311 (1.4%) were included. Asbestos exposure predominated (92%), but co-exposures were also frequent (73% crystalline silica and 48% welding fumes); 45% were active smokers at inclusion, and 37% of them agreed to consult a smoking-cessation specialist. Baseline CT scans revealed anomalies in 19 (6.1%); seven (2.4%) were diagnosed with the following stages of lung cancer: three stage IA, three stage IIA, and one stage IIB; the false-positive rate was 4.2%. Conclusion: Before considering nationwide implementation, this feasibility study provided new real-life insights finding that the selected population was indeed at high risk of lung cancer and that screening effectively detected early stages.

Indexed as

Lung cancerOccupational exposurePreventionScreening

Identifiers

PMID42206095
PMCPMC13206741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.